Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week
Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...
Hosted on MSN1h
2 Beaten-Down Dividend Stocks to Buy and Hold
Here are two brilliant options along those lines: CVS Health (NYSE: CVS) and Bristol Myers Squibb (NYSE: BMY). Find out why, ...
FierceBiotech4h
Allogene abandons leukemia plans for CAR-T in wake of Breyanzi approval
Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from ...
Why this major drugmaker no longer has an ‘IT department’
Gabriele Ricci, chief data and technology officer, has been reorganizing the technology function at Takeda Pharmaceutical.
Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now?
Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...
FiercePharma23h
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...